癌症治疗费用的上涨甚至对全民健康覆盖的地区构成了挑战。有必要评估癌症患者当前的医疗保健利用趋势，以指导公共卫生政策、资源分配和制定明智的医疗保健目标。我们分析了癌症患者在四个领域的医疗保健利用的最新趋势：药物、放射治疗（ RT）、手术和诊断程序 - 使用从 2014 年至 2019 年间韩国一家三级医院的电子病历中提取的临床数据库。计算复合调整增长率 (CAGR) 以捕获研究期间的年增长率。确定了 74,285 名癌症患者，其中分别有 40.3% (29,962)、14.2% (10,577)、31.1% (23,066) 和 92.6% (68,849) 的患者接受过至少一种抗癌药物、RT、手术和诊断程序，在此期间。我们观察到靶向免疫肿瘤药物的使用增加了 1.7 倍（从 6.8% 增加到 11.6%），调强放疗 (IMRT) 的使用增加了 21 倍（从 2014 年的 3.0% 增加到 65.7%）期间。相比之下，我们观察到接受手术治疗的患者比例持续下降，从2014年的12.2%下降到2019年的10.9%。这种下降在结肠癌（从28.5%下降到24.2%）和肝癌患者中尤其明显。从 4.1% 降至 2.9%）。从 2014 年到 2019 年，靶向免疫肿瘤药物和调强放射治疗 (IMRT) 的使用显着增加，但手术数量却有所下降。虽然有针对性的免疫肿瘤药物和 IMRT 可能会带来有希望的结果，但它们的财务影响和过度使用的可能性需要仔细监督和长期成本效益研究。© 2023 作者。约翰·威利出版的癌症医学

Rising costs of cancer treatments challenge even areas with universal health coverage. There's a need to assess current medical care utilization trends among patients with cancer to guide public health policy, resource allocation, and set informed healthcare goals.We analyzed the latest trends in medical care utilization by cancer patients in four areas-drugs, radiation therapy (RT), surgery, and diagnostic procedures-using clinical databases extracted from electronic medical records of a tertiary hospital in Korea between 2014 and 2019. Compound adjusted growth rates (CAGR) were computed to capture the annual growth over the study period.A total of 74,285 cancer patients were identified, with 40.3% (29,962), 14.2% (10,577), 31.1% (23,066), and 92.6% (68,849) of patients having received at least one anticancer agent, RT, surgery, and diagnostic procedure, respectively, over the period. We observed a 1.7-fold increase in the use of targeted · immune-oncology agents (from 6.8% to 11.6%) and a 21-fold increase (from 3.0% in 2014 to 65.7%) in intensity-modulated RT (IMRT) use over the period. In contrast, we observed a continuous decrease in the proportion of patients who underwent surgical treatment from 12.2% in 2014 to 10.9% in 2019. This decrease was particularly noticeable in patients with colon cancer (from 28.5% to 24.2%) and liver cancer (from 4.1% to 2.9%).From 2014 to 2019, there was a significant rise in the use of targeted · immune-oncology agents and IMRT, alongside a decline in surgeries. While targeted · immune-oncology agents and IMRT may offer promising outcomes, their financial impact and potential for overuse necessitate careful oversight and long-term cost-effectiveness studies.© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.